6,030 Shares in Krystal Biotech, Inc. $KRYS Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 1st quarter, Holdings Channel.com reports. The fund bought 6,030 shares of the company’s stock, valued at approximately $1,558,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Archer Investment Corp acquired a new position in Krystal Biotech during the first quarter worth $189,000. Fifth Third Bancorp grew its stake in shares of Krystal Biotech by 3,958.2% in the first quarter. Fifth Third Bancorp now owns 5,925 shares of the company’s stock valued at $1,531,000 after buying an additional 5,779 shares in the last quarter. Torray Investment Partners LLC raised its holdings in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after buying an additional 47 shares during the period. Resona Asset Management Co. Ltd. lifted its stake in Krystal Biotech by 4.5% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 3,194 shares of the company’s stock worth $825,000 after acquiring an additional 137 shares in the last quarter. Finally, Greenwood Capital Associates LLC acquired a new position in Krystal Biotech during the 1st quarter worth about $215,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 26,642 shares of company stock valued at $8,243,923. Corporate insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on KRYS shares. TD Cowen lifted their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Citigroup lifted their price objective on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Price Performance

KRYS opened at $327.50 on Friday. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $382.54. The stock has a market capitalization of $9.65 billion, a price-to-earnings ratio of 43.78 and a beta of 0.50. The business has a fifty day moving average price of $333.19 and a 200 day moving average price of $292.22.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, research analysts anticipate that Krystal Biotech, Inc. will post 7.31 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.